Lansoprazole

On August 8, the official website of China Medical Science and Technology Achievements Transformation Center (CDE) released a news that Beijing Winsunny Pharmaceutical and Nanjing EASEHEAL Pharmaceutical two companies of pioglitazone metformin tablet generic drug listing application has been officially accepted. The news quickly garnered widespread attention as it heralded the arrival of a new player in a high-profile drug market competition. Pioglitazone metformin tablets are a drug widely used to improve blood sugar control in people with type 2 diabetes. In 2023, the drug's sales in the national hospital market have exceeded 1 billion yuan, a year-on-year increase of 14.09%, ranking 12th in the diabetes treatment drug market, according to data from Yaofongyun. At present, only two companies in the market, Jiangsu Deyuan Pharma and Hangzhou Huadong Medicine, have been approved for production and passed the consistency evaluation. Pioglitazone metformin tablets are a diabetes treatment made from a combination of two active ingredients: metformin and pioglitazone. It is primarily used to treat type 2 diabetes. Its dual action mechanism is embodied in the following two aspects: First, pioglitazone effectively promotes the conversion and utilization of glucose in muscle and adipose tissue by improving the body's sensitivity to insulin, thereby improving the body's ability to regulate blood sugar. Secondly, metformin further reduces blood sugar levels by inhibiting the production of glucose in the liver, thus achieving effective control of blood sugar. The drug is effective, can effectively control fasting blood glucose and postprandial blood glucose, improve the metabolic disorders of diabetes. It can also delay the development of type 2 diabetes and prevent and reduce the occurrence of complications. Pioglitazone metformin tablets have a good safety profile, do not cause common insulin treatment side effects such as hypoglycemia, and can reduce the risk of cardiovascular disease, cardiometabolic protection. In addition, the drug only needs to be taken once a day and is convenient to administer, helping to improve patient compliance. The application of Beijing Winsunny Pharmaceutical and Nanjing EASEHEAL Pharmaceutical was accepted, indicating that China will have a third pharmaceutical company qualified to produce this diabetes treatment drug. This will undoubtedly provide more options for patients and could increase competition among Chinese pharmaceutical companies. In recent years, Beijing Winsunny Pharmaceutical has been active in the application of new drugs, including 18 varieties including bromohexine hydrochloride oral solution, Lansoprazole enteric capsules, etc., are being declared. Nanjing EASEHEAL Pharmaceutical also recently has a number of generic drugs in the review stage, such as voriconazole dry suspension, Indapamide sustained-release tablets. With the addition of more players, the pioglitazone metformin tablet market is expected to become more diversified, offering more quality treatment options for patients with diabetes. This will undoubtedly drive continued innovation in the field and let us look forward to the future.

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月8日，据CDE官网公示，北京福元医药（受理号CYHS2402527）、南京易亨制药（受理号CYHS2402526）2家药企提交的3类仿制药吡格列酮二甲双胍片上市申请已获受理。目前，吡格列酮二甲双胍片在国内仅2家药企获批并通过一致性评价。 截图来源：CDE 吡格列酮二甲双胍片用于改善2型糖尿病人的血糖控制，适用于单独使用盐酸二甲双胍治疗效果不佳的病人，以及使用盐酸吡格列酮和盐酸二甲双胍联合治疗的病人。据药融云数据库显示，吡格列酮二甲双胍片在2023年全国院内市场的销售额超10亿元，同比增长达14.09%。在2023年全国医院内糖尿病治疗药物销售排行榜中，吡格列酮二甲双胍片以3.21%的市场份额，跻身TOP12品种之列。 截图来源：药融云全国医院销售数据库 据药融云数据库显示，吡格列酮二甲双胍片在国内仅江苏德源药业、杭州中美华东制药2家药企获批并通过一致性评价。截至目前，吡格列酮二甲双胍片有成都倍特药业、北京福元医药、山东齐都药业等11家企业报产在审。此次，北京福元医药、南京易亨制药2家药企以仿制3类报产获受理，若能顺利获批，国产第3家有望后来者居上。 截图来源：药融云中国药品审评数据库 2024年至今，北京福元医药（含子公司）有盐酸溴己新口服溶液、吡格列酮二甲双胍片、兰索拉唑肠溶胶囊等18个品种提交了仿制申请，均在审评审批中。 截图来源：药融云中国药品审评数据库 今年以来，南京易亨制药有伏立康唑干混悬剂、吡格列酮二甲双胍片、吲达帕胺缓释片、甲磺酸多沙唑嗪缓释片 、米拉贝隆缓释片5个品种提交了仿制申请，均在审评审批中。 END 本文为原创文章，转载请留言获取授权  近期热门资源获取 后台回复关键词“报告”，获取数十篇药融云出品独家报告 后台回复关键词“CSCO”，获取2023CSCO指南 后台回复关键词“ASCO”，获取2023ASCO分癌种摘要 后台回复关键词“2023首仿”，获取2023年首仿药物获批名单 后台回复关键词“医保”，获取2022年医保目录    联系我们，体验药融云更多专业服务 会议 合作 园区 服务 数据库 咨询 定制 服务 媒体 合作 点击阅读原文，申请药融云企业版免费试用！